Abstract: The present invention relates to a process for the fermentative continuous production of erythropoietin, where eukaryotic erythropoietin-producing cells are cultured in a perfusion reactor while retaining the cells, the glucose concentration in the culture supernatant being adjusted via the perfusion rate and the cell number via the cell retention rate and/or the outward transferal of defined amounts of cell-containing culture medium from the bioreactor within preset zones.

Abstract: The present invention relates to a method for preparing erythropoietin, wherein culture supernatant of erythropoietin-producing eukaryotic cells containing erythropoietin are subjected to the following steps: a) Removing the cell components; and b) treating the product from a) to the following chromatography steps in the sequence indicated i) reversed phase chromatography; ii) anion exchange chromatography; iii) hydroxyapatite chromatography.

Abstract: The present invention provides a process for the control of a biological rification stage of the aerobic activated sludge type, wherein at least one of the micro-organisms most frequently present in the activated sludge is continuously monitored with regard to the amount thereof in that, in a representative sample from the activated sludge and/or from the inlet of the activated sludge tank, this micro-organism is bound to fluorescence-labelled antibodies directed against the chosen micro-organism or this micro-organism is allowed to react with a fluorogenic substrate by means of a special metabolic ability, the amount of the thus fluorescence-labelled micro-organism is determined by flow cytometry and, at the same time, the total amount of the micro-organism present is determined by scattered light measurement and/or coloration of the DNA and, depending upon the measurement values thus obtained, the amount of at least one particular micro-organism and/or the growth conditions for this micro-organism is regula

Abstract: Fragments of Alpha-1 thymosin ranging from two to twelve peptides in length nd pharmaceutically acceptable salts thereof. These fragments possess immunostimulatory and immunoregulatory properties similar to the alpha thymosin molecule and are useful in the same fashion as in this molecule.

Abstract: Peptide fragments of the alpha thymosin molecule, ranging from four to eighteen peptides in length, and salts thereof, are disclosed. These fragments possess immunostimulatory and immunoregulatory properties similar to the alpha thymosin molecule, and are useful in the same fashion as in this molecule.

Abstract: For the preparation of polyfunctional organic compounds having at least one functional group of medium nucleophilic character selectively blocked by a tertiary butyl group, the corresponding unblocked compound is dissolved in a solution of concentrated sulfuric acid in an organic ether, and excess liquid isobutene is added to the solution at a temperature of not more than 5.degree. C.

Abstract: The Thymosin alpha 1 fragment compound Glu-Ala-Glu-Asn-OH.

Abstract: Polypeptides of the sequence Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile--Thr-Lys-Asp-Leu-Lys-Glu-Lys- Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn, wherein at least one of the amino acids 10,15,21,25 and/or 28 is present as amide or alkyl amide, and/or amino acid 1 bears an acyl group other than acetyl, having up to 6 carbon atoms, especially an acyl glycine residue. In addition, certain thymosin fragments I to VII are provided and process for producing the substituted thymosin alpha.

Abstract: Bis-thymosine .alpha.-1 consisting of two desacetylthymosine .alpha.-1 un N-terminally linked by a bridge bond of 1 to 10 carbon atoms, especially an .alpha.,.omega.-diacyl residue with 2 to 10 carbon atoms. This new compound is made by converting a synthetic desacetylthymosine .alpha.-1 in which all functional groups of amino acids 1 through 28, except the N-terminal group, are blocked by protective groups conventional in peptide synthesis with a coupling compound of 1 to 10 carbon atoms and that reacts with NH.sub.2 groups, in a polar solvent, and then removing the protective groups.

Abstract: Polypeptides of the sequence Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Ly s-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn, wherein at least one of the amino acids 10, 15, 21, 25 and/or 28 is present as amide or alkyl amide, and/or amino acid 1 bears an acyl group other than acetyl, having up to 6 carbon atoms, especially an acyl glycine residue. In addition, certain thymosin .alpha..sub.1 fragments I to VII are provided.

Abstract: A process for the selective formation of at least two disulfide bridges in a polypeptide which process comprises treating a polypeptide starting material carrying at least two SH-groups to mask at least one of said SH-groups with a p-methoxybenzyl protective group and to mask at least one of the SH-groups with an acetamido methyl protective group, then splitting-off said p-methoxybenzyl protective group with pyridine-polyhydrogen fluoride in the presence of anisol, and then treating with iodine in an acid solution to produce said disulfide bridge-containing polypeptide.

Abstract: The present invention relates to a method for the preparation of polypeptides by the stepwise condensation of amino acids on a solid support material, which material comprises condensing, as a starting material, amino acids having an N-terminal of .alpha.,.alpha.-dimethyl-3,5-dimethoxybenzyloxycarbonyl, or peptide fragments which are N-terminally protected, utilizing as the support material a slightly cross-linked carrier material activated with bromoacetyl bromide with the formation of bromoacetyl phenyl groups, splitting off, in the course of the synthesis, the peptide fragments formed, separating same from contaminating by-products, and binding them again to the support material.